The global lung cancer surgery market is witnessing steady growth driven by several factors. The increasing prevalence of lung cancer, particularly among smokers and individuals exposed to air pollution, is a primary driver of market growth. Additionally, advancements in surgical techniques, including minimally invasive procedures and robotic-assisted surgery, are improving surgical outcomes and reducing post-operative complications, thus driving the demand for lung cancer surgery. Furthermore, growing awareness about the benefits of early detection and treatment, coupled with the expanding healthcare infrastructure in developing regions, is expected to further fuel market growth. However, high costs associated with advanced surgical procedures and limited access to healthcare facilities in some regions could hinder market growth to some extent. Nonetheless, ongoing research and development activities aimed at enhancing surgical techniques and improving patient outcomes are expected to create lucrative opportunities for market players.
The Global Lung Cancer Surgery Market size is projected to reach USD 5,092.07 million by 2029, with a CAGR of 5.5% during the forecast period of 2022 to 2029.
To know more, visit https://www.databridgemarketresearch.com/jp/reports/global-lung-cancer-surgery-market
Below are the Top Five Lung Cancer Surgery Companies with a Significant Market Share:
|
Rank
|
Company
|
Overview
|
Product Portfolio
|
Sales Geographical Coverage
|
Developments
|
|
1.
|
Johnson & Johnson Services, Inc.
|
Johnson & Johnson Services, Inc. is a prominent player renowned for its diversified healthcare products and services. The company's commitment to innovation and patient-centric solutions is reflected in its range of advanced surgical equipment and technologies. Johnson & Johnson's offerings in lung cancer surgery include minimally invasive surgical instruments, imaging systems, and robotic-assisted surgery platforms.
|
|
Asia, Europe, America, Middle East and Africa
|
In June 2022, Ethicon, a subsidiary of Johnson & Johnson Services, INC., announced the U.S. launch of the ECHELON 3000 Stapler, a digitally enabled device that provides surgeons with simple, one-handed powered articulation to help address the unique needs of their patients. The features combined with software that provides real-time haptic and audible device feedback enable surgeons to make critical adjustments during procedures.
|
|
2.
|
Accuray Incorporated
|
Accuray Incorporated is a key player known for its innovative radiation therapy solutions. The company's flagship product, the CyberKnife System, is a robotic radiosurgery system that enables precise, non-invasive treatment of lung tumors. Accuray's focus on personalized care and advanced technology has positioned it as a leader in the field of lung cancer surgery, offering patients and healthcare providers innovative treatment options with improved outcomes.
|
|
U.S., Europe, Asia-Pacific
|
In September 2022, Accuray Incorporated announced that the company is joining forces with Genolier Innovation Hub, a fully-owned subsidiary of AEVIS VICTORIA SA (SWX: AEVS), in support of a unique new approach to improving patient care. The collaboration has subsequently increased the growth of the company.
|
|
3.
|
Intuitive Surgical
|
Intuitive Surgical is a leading innovator in robotic-assisted surgery, with its da Vinci Surgical System being a key technology in the market. The da Vinci System enables surgeons to perform minimally invasive procedures with enhanced precision and control, leading to faster recovery times and reduced complications for patients undergoing lung cancer surgery. Intuitive Surgical's commitment to advancing surgical technology and improving patient outcomes makes it a significant player.
|
|
North America, Middle East and Africa, Europe, Asia-Pacific
|
In December 2021, Intuitive Surgical, a leader in minimally invasive care and the pioneer of robotic-assisted surgery, announced that the U.S. Food & Drug Administration (FDA) cleared the company’s fully wristed, 8 mm SureForm 30 Curved-Tip Stapler and reloads (gray, white, and blue) for use in general, thoracic, gynecologic, urologic, and pediatric surgery. This development will help the organization to become a market leader in the field of medical devices.
|
|
4.
|
FUJIFILM Holdings Corporation
|
FUJIFILM Holdings Corporation offers a range of diagnostic imaging and surgical solutions. The company's advanced imaging systems and endoscopy equipment play a crucial role in the early detection and diagnosis of lung cancer, facilitating more effective treatment planning and surgical interventions. With a focus on innovation and quality, FUJIFILM Holdings Corporation is a trusted partner for healthcare providers seeking to improve outcomes in lung cancer surgery.
|
|
North America, Middle East and Africa, Latin America, Europe, Asia-Pacific and Oceania
|
In September 2021, FUJIFILM Corporation announced that the “FDR Xair System,” which combines the portable X-ray unit “FDR Xair” and the digital X-ray diagnostic imaging device (Cassette DR) “FDR D-EVO II”, added to the Diagnostics Catalog of medical devices as a recommended chest X-ray system for tuberculosis (TB) diagnosis. The launch helps the organization to generate more revenue.
|
|
5.
|
Ambu A/S
|
Ambu A/S specializes in single-use endoscopy products and solutions. The company's innovative devices, such as bronchoscopes and endoscopic ultrasound systems, are designed to enhance the safety and efficacy of lung cancer diagnostic and therapeutic procedures. Ambu's commitment to quality and patient safety, combined with its focus on disposable, cost-effective solutions, makes it a valuable contributor to the advancement of lung cancer surgery worldwide.
|
|
North America, Europe, South America, Asia-Pacific
|
In July 2022, Ambu announced FDA clearance for Ambu aScopeTM 5 Broncho, Following Earlier European Regulatory Approval. Ambu is set to commence commercialization of the aScope 5 Broncho and the full high-definition Ambu aBoxTM 2 processing unit in both Europe and the U.S.With the introduction of the aScope 5 Broncho, Ambu establishes a leading position in the adoption of single-use endoscopes within the bronchoscopy suite, a segment recognized for its highly intricate medical procedures.
|
Conclusion
The global lung cancer surgery market is poised for significant expansion, driven by factors such as the rising prevalence of lung cancer, technological advancements in surgical procedures, and increasing awareness about early detection and treatment. Market players are focusing on developing innovative surgical techniques and advanced technologies to enhance patient outcomes and reduce healthcare costs. While challenges such as high treatment costs and limited access to healthcare in some regions exist, the overall outlook for the market remains positive. Continued investment in research and development, along with efforts to improve healthcare infrastructure, will be crucial in sustaining the growth of the global lung cancer surgery market and improving outcomes for patients worldwide.
